PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsCetrorelix
Cetrotide(cetrorelix)
Cetrorelix, Cetrotide (cetrorelix) is a protein pharmaceutical. Cetrorelix was first approved as Cetrotide on 1999-04-12. It is used to treat ovarian hyperstimulation syndrome in the USA. It has been approved in Europe to treat ovulation and ovulation induction. The pharmaceutical is active against gonadotropin-releasing hormone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
endocrine system diseasesD004700
therapeuticsD013812
investigative techniquesD008919
reproductive and urinary physiological phenomenaD012101
Trade Name
FDA
EMA
Cetrorelix, Cetrotide (discontinued: Cetrotide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cetrorelix acetate
Tradename
Company
Number
Date
Products
CETROTIDEEMD SeronoN-021197 RX2000-08-11
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cetrorelixANDA2024-06-30
cetrorelix acetateANDA2024-08-08
cetrotideNew Drug Application2024-06-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ovarian hyperstimulation syndrome—D016471—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01C: Hypothalamic hormones
— H01CC: Anti-gonadotropin-releasing hormones
— H01CC02: Cetrorelix
HCPCS
No data
Clinical
Clinical Trials
131 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfertilityD007246HP_0000789—21211242468
Female infertilityD007247EFO_0008560N971353515
Polycystic ovary syndromeD011085EFO_0000660E28.22234413
SyndromeD013577——1133512
Fertilization in vitroD005307—————7310
Ovarian hyperstimulation syndromeD016471——1521310
Intracytoplasmic sperm injectionsD020554—————5—5
Assisted reproductive techniquesD027724———21115
FertilityD005298—————123
LeiomyomaD007889HP_0000131D2511—1—2
Show 10 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Preimplantation diagnosisD019836————3—14
Prostatic hyperplasiaD011470EFO_0000284N40——3——3
HypertrophyD006984EFO_0002460———3——3
OogenesisD009866————1——1
ParentsD010290————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovulation inductionD010062———2——13
Breast neoplasmsD001943EFO_0003869C5012———2
Ectopic pregnancyD011271—O0011——12
EndometriosisD004715EFO_0001065N8012———2
Primary ovarian insufficiencyD016649EFO_0004266E28.312———2
Male breast neoplasmsD018567——11———1
InfectionsD007239EFO_0000544—11———1
SalpingitisD012488—N70.9111———1
Premature menopauseD008594HP_0008209E28.3111———1
Rheumatoid arthritisD001172EFO_0000685M06.9—1———1
Show 1 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AgingD000375GO_0007568R41.811————1
MenopauseD008593EFO_0003922N951————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.9————22
Healthy volunteers/patients———————11
Diabetes mellitusD003920HP_0000819E08-E13————11
Type 1 diabetes mellitusD003922EFO_0001359E10————11
Premature cardiac complexesD005117—I49.40————11
Ovarian pregnancyD065172—O00.2————11
PremenopauseD017697——————11
Female genital diseasesD005831EFO_0009549N85————11
Acupuncture therapyD015670——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCetrorelix
INNcetrorelix
Description
CETRORELIX
Classification
Protein
Drug classhormone-release inhibiting peptides
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Identifiers
PDB—
CAS-ID120287-85-6
RxCUI—
ChEMBL IDCHEMBL1200490
ChEBI ID59224
PubChem CID16130924
DrugBankDB00050
UNII IDOON1HFZ4BA (ChemIDplus, GSRS)
Target
Agency Approved
GNRHR
GNRHR
Organism
Homo sapiens
Gene name
GNRHR
Gene synonyms
GRHR
NCBI Gene ID
Protein name
gonadotropin-releasing hormone receptor
Protein synonyms
gnRH receptor, gnRH-R, gonadotropin-releasing hormone (type 1) receptor 1, leutinizing hormone releasing horomone receptor, leutinizing-releasing hormone receptor, luliberin receptor, type I GnRH receptor
Uniprot ID
Mouse ortholog
Gnrhr (14715)
gonadotropin-releasing hormone receptor (Q61611)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,446 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
545 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use